相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Urinary soluble CD163 as a biomarker of disease activity and relapse in antineutrophil cytoplasm antibody-associated glomerulonephritis
Javier Villacorta et al.
CLINICAL KIDNEY JOURNAL (2021)
Immune checkpoint inhibitor therapy-associated graft intolerance syndrome in a failed kidney transplant recipient
Christina D. Mejia et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
Onconephrology: The intersections between the kidney and cancer
Mitchell H. Rosner et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma
Irene Tsung et al.
ONCOLOGIST (2021)
A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease
Abhijat Kitchlu et al.
KIDNEY INTERNATIONAL REPORTS (2021)
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer
R. Perets et al.
ANNALS OF ONCOLOGY (2021)
Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study
Yoshinosuke Shimamura et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2021)
A real or apparent decrease in glomerular filtration rate in patients using olaparib?
M. A. C. Bruin et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition
Samy Hakroush et al.
FRONTIERS IN IMMUNOLOGY (2021)
Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report
Matthew Mulroy et al.
IMMUNOTHERAPY (2021)
Cytokine storm induced by a PD1 inhibitor in a renal transplant patient
Arnaud Del Bello et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review
Lee S. Nguyen et al.
EUROPEAN JOURNAL OF CANCER (2021)
Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review
Juliya Fisher et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
Mark A. Perazella et al.
KIDNEY INTERNATIONAL (2020)
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study
Frank B. Cortazar et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
M2 macrophages predict worse long-term outcomes in human acute tubular necrosis
Myung-Gyu Kim et al.
SCIENTIFIC REPORTS (2020)
Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC
Daphne W. Dumoulin et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer A case report
Katsuyuki Tanabe et al.
MEDICINE (2020)
Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia
Ali Yilmaz et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma
R. Kelley et al.
ANNALS OF ONCOLOGY (2020)
Checkpoint inhibitor-related renal vasculitis and use of rituximab
Omar Mamlouk et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
Sara Zalba et al.
PHARMACEUTICS (2020)
Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
Sandra M. Herrmann et al.
KIDNEY INTERNATIONAL REPORTS (2020)
Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors A systematic review and meta-analysis
Bi-Cheng Wang et al.
MEDICINE (2020)
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Rossana Franzin et al.
FRONTIERS IN IMMUNOLOGY (2020)
Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma
Viral Patel et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity?
Erin Vaughan et al.
CANCER REPORTS (2020)
Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy Single Center Experience of Management and Drug Rechallenge
Sandhya Manohar et al.
KIDNEY360 (2020)
Rapidly Progressive Acute Kidney Injury Associated with Nivolumab Treatment
Sachi Okawa et al.
CASE REPORTS IN ONCOLOGY (2020)
Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database
Quentin Scanvion et al.
ONCOIMMUNOLOGY (2020)
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Maddalena Centanni et al.
CLINICAL PHARMACOKINETICS (2019)
Management of Immunotherapy-Related Toxicities. Version 1.2019
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Defining real-world criteria for immune-related adverse events (irAEs).
Prabhsimranjot Singh et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis
Joe-Elie Salem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
Valerie Glutsch et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
98P Results from a phase I study of MK-1308 (anti–CTLA-4) plus pembrolizumab in previously treated advanced small cell lung cancer
B C Cho et al.
ANNALS OF ONCOLOGY (2019)
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors
Harish Seethapathy et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Filipe Martins et al.
LANCET ONCOLOGY (2019)
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
Omar Mamlouk et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis
David Qualls et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Renal toxicities associated with pembrolizumab
Hassan Izzedine et al.
CLINICAL KIDNEY JOURNAL (2019)
The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature
Akifumi Tabei et al.
INTERNAL MEDICINE (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report
Naoki Takahashi et al.
LUNG CANCER (2018)
Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report
Ryo Koda et al.
BMC NEPHROLOGY (2018)
Acute Kidney Injury after Pembrolizumab-Induced Adrenalitis and Adrenal Insufficiency
Ramy M. Hanna et al.
CASE REPORTS IN NEPHROLOGY AND DIALYSIS (2018)
Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy
Sandy El Bitar et al.
CASE REPORTS IN ONCOLOGICAL MEDICINE (2018)
Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report
Robin A. Daanen et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma
Lea Bottlaender et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy
Pragathi Balakrishna et al.
CASE REPORTS IN ONCOLOGICAL MEDICINE (2017)
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Rimda Wanchoo et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S. Champiat et al.
ANNALS OF ONCOLOGY (2016)
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Frank B. Cortazar et al.
KIDNEY INTERNATIONAL (2016)
Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis
Nobuhide Endo et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
Naoka Murakami et al.
CLINICAL KIDNEY JOURNAL (2016)
Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms
Daniel C. Brennan et al.
REVIEWS IN MEDICAL VIROLOGY (2013)
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Ron J. Keizer et al.
CLINICAL PHARMACOKINETICS (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anti-CTLA4 Antibody-Induced Lupus Nephritis.
Fouad Fadel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis
HL Ding et al.
CLINICAL IMMUNOLOGY (2005)
分享论文
